South Korean (KOSPI) Pharma Industry Analysis

UpdatedJan 19, 2022

DataAggregated Company Financials

Companies96

7D-7.6%
3M-14.5%
1Y-35.2%
YTD-12.0%

Over the last 7 days, the Pharma industry has dropped 7.6%, driven by a decline by Celltrion Pharm of 19%. However, the industry is down 35% over the past year.

Industry Valuation and Performance

Has the South Korean Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE
Wed, 19 Jan 2022	₩54.1t	₩25.0t	₩934.5b	22.2x
Fri, 17 Dec 2021	₩61.6t	₩25.0t	₩934.5b	26.4x
Sun, 14 Nov 2021	₩59.7t	₩24.7t	₩875.4b	23.6x
Tue, 12 Oct 2021	₩62.4t	₩24.7t	₩876.1b	23.7x
Thu, 09 Sep 2021	₩71.2t	₩26.0t	₩960.6b	38.3x
Sat, 07 Aug 2021	₩72.1t	₩25.3t	₩928.3b	41.5x
Fri, 30 Apr 2021	₩69.3t	₩24.9t	₩915.5b	34.8x
Mon, 01 Feb 2021	₩76.0t	₩24.6t	₩897.5b	35.5x
Thu, 05 Nov 2020	₩68.8t	₩24.4t	₩499.4b	27.5x
Sun, 09 Aug 2020	₩69.8t	₩24.0t	₩524.2b	27.7x
Sat, 02 May 2020	₩40.3t	₩23.6t	₩732.3b	21.1x
Tue, 04 Feb 2020	₩37.2t	₩23.1t	₩621.5b	26.6x
Fri, 08 Nov 2019	₩39.4t	₩21.8t	₩547.5b	24.5x
Thu, 01 Aug 2019	₩37.1t	₩21.1t	₩625.0b	23.4x
Sun, 05 May 2019	₩48.3t	₩20.5t	₩650.4b	33.4x
Wed, 06 Feb 2019	₩47.7t	₩20.1t	₩604.9b	43.4x

PE Ratio

43.4x

Wed, 06 Feb 2019

Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 22.2x which is lower than its 3-year average PE of 29.8x. It appears they believe that earnings will not grow as fast as they have historically.

Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have grown 16% per year over the last three years, and revenues for these companies have grown 7.5% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Pharma industry?


Pharma	-7.62%

Industry PE: Investors are most optimistic about the Pharma industry even though it's trading below its 3-year average PE ratio of 29.8x. This is likely because analysts are expecting annual earnings growth of 28%, which is higher than its past year's earnings decline of 18% per year.

Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 28% over the next 5 years. This is better than its past earnings decline of 18% per year.